Pfizer seeks approval for new Viagra use

Share this article:
Pfizer has filed applications with the FDA and European regulators for approval of its male impotence drug Viagra to treat the potentially fatal lung disorder pulmonary arterial hypertension.
The drug would be called Revatio for the new indication, not Viagra, and would be manufactured and marketed in a different dosage, color and shape than Viagra, the New York-based drug maker said.
Pulmonary arterial hypertension treatments include calcium channel blocker drugs Norvasc and Procardia XL, also manufactured by Pfizer and Biovail's Cardizem.
An approval would add to worldwide sales of Viagra, which generated $1.9 billion in revenue for 2003, according to a Bloomberg News report.
Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.